Clsa Sees Limited Hit To Hospitals From India's Cancer: drug margin cap

Max Healthcare Institute

12/10/2026 05:01

** India's move to cap margins on anti-cancer drugs at 30% could lower prices by 20%-70% and save patients about 25 billion rupees (about $261 million) annually, CLSA says  
** The measure targets excessive mark-ups by distributors, retailers and hospitals, with limited direct impact on drugmakers, brokerage says 
** CLSA expects the impact on revenue at Apollo Hospitals APLH.NS, Max Healthcare MAXE.NS and Medanta GLOH.NS to be minimal given their diversified operations
** The brokerage, however, estimates a temporary 2%-5% margin impact for hospitals as oncology drugs are typically high-margin products
** CLSA says operators may seek to offset the hit by raising prices across other services


($1 = 95.7600 Indian rupees)

 (Reporting by Kashish Tandon in Bengaluru)
 ((Kashish.tandon@thomsonreuters.com))